Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit
I'm PortAI, I can summarize articles.
Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics Inc. (NASDAQ: CORT) stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misled investors regarding the viability of its product candidate, relacorilant, for treating hypercortisolism. The FDA raised concerns about the clinical evidence supporting Corcept's New Drug Application, leading to a significant stock price drop after the FDA issued a Complete Response Letter on December 31, 2025. Shareholders may be eligible to participate in the class action.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments